Home » Reports » Broker Ratings » Hikma Pharmaceuticals Plc 24.3% Potential Decrease Indicated by Barclays Capital

Hikma Pharmaceuticals Plc 24.3% Potential Decrease Indicated by Barclays Capital

Hikma Pharmaceuticals Plc using EPIC/TICKER code (LON:HIK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘UNDERWEIGHT’ today by analysts at Barclays Capital. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set their target price at 850 GBX on its stock. This now indicates the analyst believes there is a potential downside of -24.3% from today’s opening price of 1122.5 GBX. Over the last 30 and 90 trading days the company share price has increased 182.1 points and increased 54.5 points respectively. The 1 year high stock price is 2200 GBX while the 52 week low for the stock is 814.2 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 973.05 GBX and a 200 Day Moving Average share price is recorded at 1,181.44. There are currently 240,678,912 shares in issue with the average daily volume traded being 858,457. Market capitalisation for LON:HIK is £2,619,789,957 GBP.

Follow this article (for updates)
X

Follow this article (for updates)

E-mail : *
* Your personal data will be used to support your experience throughout this website and for other purposes described in our Privacy Policy. I hereby agree and consent to the privacy policy.